Skip to main content
. 2023 Dec 1;23:484. doi: 10.1186/s12890-023-02749-1

Table 1.

Clinical characteristics of patients who underwent genome biopsy with TBB

Total patients (n = 572) (%) TBB patients (n = 236) (%) Re-biopsy in TBB patients (n = 24) (%)
Age-median, [range] Median 68 [25–93] 68 [25–93] 67 [25–79]
Sex-no. (%) Male 365 (63.8) 143 (60.6) 10 (41.6)
Female 207 (36.2) 93 (39.4) 14 (58.4)
Histology-no. (%) Ad including 396 (69.2) 160 (67.8) 14 (58.4)
 Ad + SCLC 2 0 0
 Ad + Sq 2 0 0
Sq 99 (17.3) 50 (21.2) 5 (20.8)
NSCLC 77 (13.5) 26 (11.0) 5 (20.8)
Stage-n. (%) IVA, B 416 (72.7) 171 (72.5) 21 (87.5)
IIIA,B,C 140 (24.5) 55 (23.3) 3 (12.5)
IIA, B 16 (2.8) 10 (4.2) 0
Tumor location.1 Central 69 (29.2) 14 (58.4)
Peripheral 167 (70.8) 10 (41.6)
Tumor location.2 Right
 Upper and Middle 82 (34.7) 10 (41.6)
 Lower 42 (17.8) 6 (25.0)
Left
 Upper 67 (28.4) 4 (16.7)
 Lower 45 (19.1) 4 (16.7)
Maximum diameter of tumor.(mm) Median [range] 39.3 [14.7–102.3] 49.5 [15.6–82.0]
ROSE Positive 21 (87.5)

TBB transbronchial biopsy, Ad adenocarcinoma, SCLC small cell lung carcinoma, Sq squamous cell carcinoma, ROSE rapid-onsite evaluation